MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock and...
$269,903K
Proceeds from issuance of
common stock under...
$21,006K
Proceeds from issuance of
common stock under...
$263K
Proceeds from issuance of
common stock upon...
$59K
Net cash provided by
financing activities
$289,633K
Canceled cashflow
$1,598K
Net change in cash
and cash...
$3,016K
Canceled cashflow
$286,617K
Payments for taxes
related to net share...
$1,598K
Stock-based compensation
$14,531K
Accrued expenses
$4,150K
Other noncurrent
liabilities
$877K
Amortization of debt discount
and accretion of...
$773K
Noncash operating lease
expense
$316K
Depreciation
$18K
Proceeds from sales and
maturities of marketable...
$212,131K
Net cash used in
operating activities
-$172,162K
Net cash used in
investing activities
-$114,455K
Canceled cashflow
$20,665K
Canceled cashflow
$212,131K
Net loss
-$182,779K
Purchases of marketable
securities
$326,514K
Net accretion of
discounts on investments...
$4,224K
Prepaid expenses and
other assets
$4,202K
Accounts payable
-$752K
Change in fair value of
warrant liability
-$516K
Operating lease
liabilities
-$354K
Purchases of property and
equipment
$72K
Back
Back
Cash Flow
source: myfinsight.com
89bio, Inc. (ETNB)
89bio, Inc. (ETNB)